MTOR and influenza: In addition, previous researches have demonstrated that pneumovax is effective in preventing both influenza (in 70–80% of people) and pneumococcal infection (in 60–70% of people) [52], [53], thus it might be a potential effective therapy for preventing mTOR inhibitors related pneumovax in cancer patients.